

Snapshot

Ticker	SKGIX
Morningstar Category	US Fund Small Growth
Inception Date	11/15/2021
Prospectus Dated	8/28/22
Total AUM - All Classes	\$23,293,174
Average Market Cap (Mil)	\$3,690
# of Holdings	90

Portfolio Managers

Brent Lium, CFA

Strategy Objective

Seeks to provide long-term capital appreciation

Risk Statistics

Time Period: 11/15/2021 to 12/31/2022

Calculation Benchmark: Russell 2000 Growth

Std Dev	21.90
Beta	0.84
Annualized Alpha	-10.90
R2	95.48
Sharpe Ratio (arith)	-1.48
Up Capture Ratio	71.00
Down Capture Ratio	100.68


Characteristics

Dividend Payout Ratio (%)	0.00
Dividend Growth, 3 Yr Hist (%)	3.60
EPS Growth, 3 Yr Hist (%)	20.75
Price/Earnings Ratio - NTM	17.58
Price/Book Ratio	3.86
Price/Free Cash Flow, TTM	16.40
Return on Equity, TTM (%)	4.97

Top 10 Holdings

	Weight
Box, Inc. Class A	2.60%
HealthEquity Inc	2.37%
Iridium Communications Inc.	2.37%
Cboe Global Markets Inc	2.14%
Inspire Medical Systems, Inc.	2.08%
Academy Sports and Outdoors, Inc.	1.91%
Shockwave Medical, Inc.	1.90%
Qualys, Inc.	1.89%
World Wrestling Entertainment, Inc. Class A	1.75%
Halozyne Therapeutics, Inc.	1.72%
Total	20.74%

Performance (%)



	1 Quarter	YTD	1 Year	Inception
Steward Small Cap Growth Fund	0.43%	-30.94%	-30.94%	-31.84%
Russell 2000 Growth	4.13%	-26.36%	-26.36%	-29.33%

Investment Growth of \$10,000

Time Period: 11/15/2021 to 12/31/2022



All Investments are subject to risks, including the possible loss of principal. Past performance does not guarantee future results. Index returns shown assume the reinvestment of all dividends and distributions.

Expense Ratios (%)

	Class Institutional Shares
Gross Expense Ratio	1.31%
Net Expense Ratio	1.00%

The net expense ratio reflects a contractual commitment by the Fund's investment adviser to waive fees and/or reimburse expenses through August 27, 2023. Absent the waiver and/or reimbursement, expenses would be higher and total returns would be less. Please see the prospectus for details.

Leading Contributors

Time Period: 9/30/2022 to 12/31/2022


	Return	Contribution
Halozyme Therapeutics, Inc.	43.90	0.88
Inspire Medical Systems, In...	42.01	0.57
Box, Inc. Class A	27.63	0.53
BioXcel Therapeutics, Inc.	81.73	0.48
Lancaster Colony Corporatio...	31.84	0.44
Outset Medical, Inc.	62.08	0.41
Lattice Semiconductor Corpo...	31.84	0.38
Academy Sports and Outdoors...	24.74	0.36
Medpace Holdings, Inc.	35.15	0.33
Grand Canyon Education, Inc...	28.46	0.32

Leading Detractors

Time Period: 9/30/2022 to 12/31/2022

	Return	Contribution
TechTarget, Inc.	-25.57	-0.30
Pacira Biosciences, Inc.	-27.41	-0.33
DigitalOcean Holdings, Inc.	-29.58	-0.42
Plug Power Inc.	-41.12	-0.42
Qualys, Inc.	-19.48	-0.43
Chart Industries, Inc.	-37.49	-0.47
Omniceil, Inc.	-42.07	-0.47
Shockwave Medical, Inc.	-26.06	-0.62
Silvergate Capital Corp. Cl...	-76.91	-0.68
R1 RCM Inc	-40.91	-0.69


Sector Allocation



	%
Communication Services	5.60
Consumer Discretionary	9.24
Consumer Staples	4.96
Energy	3.96
Financials	4.34
Health Care	24.55
Industrials	15.71
Information Technology	22.94
Materials	3.55
Real Estate	2.55
Utilities	2.59
Total	100.0

Sector Exposure Relative to Benchmark

Calculation Benchmark: Russell 2000 Growth



The Steward Funds are distributed by **Crossmark Distributors, Inc., member FINRA**. Crossmark Distributors is an affiliate of Crossmark Global Investments, Inc., the Steward Funds' investment adviser. Crossmark Global Investments is an investment adviser registered with the Securities and Exchange Commission that provides discretionary investment management services to mutual funds, institutions, and individual clients.

Past performance is no guarantee of future results. Investment return and principal value will fluctuate so that shares, when redeemed, may be worth more or less than their original cost. The Fund's current performance may be lower or higher than quoted. Before investing in a mutual fund, you should read the fund's prospectus carefully and consider the fund's investment objectives, risks, charges, and expenses. The prospectus contains this and other information about the fund. To obtain Fund performance as of the most recent month-end or to obtain a copy of the Steward Funds' prospectus free of charge, call Crossmark Distributors at 888.845.6910.

The Fund may not achieve its objective if the managers' expectations regarding particular securities or markets are not met. Equity investments generally involve two principal risks—market risk and selection risk. The value of equity securities will rise and fall in response to general market and/or economic conditions (equity market risk). The value of any individual equity security will rise and fall in response to the market's perception of the issuer's revenues, earnings, balance sheet, credit worthiness, business plan, and overall perception of the viability of the issuer's business (selection risk).

Small-cap investments may be subject to smaller companies risk. Stocks of smaller, less seasoned companies are generally subject to greater price fluctuations, less liquidity, higher transaction costs, and higher investment risk than those of larger, more seasoned issuers. Smaller companies may have limited product lines, markets, or financial resources, and they may be dependent on a limited management group or lack substantial capital reserves or an established performance record. There is generally less publicly available information about such companies than for large, more established companies.

The Fund's values-based screening policies exclude certain securities issuers from the universe of otherwise available investments. As a result, the Fund may not achieve the same level of performance as it otherwise would have in the absence of the screening process. If the Fund has invested in a company that is later discovered to be in violation of one or more screening criteria and liquidation of an investment in that company is required, selling the securities at issue could result in a loss to the Fund. Further, the Fund's values-based screening policies may prevent the Fund from participating in an otherwise suitable investment opportunity.

The Russell 2000® Growth Index measures the performance of the small-cap growth segment of the U.S. equity universe. It includes those Russell 2000 companies with relatively higher price-to-book ratios, higher I/B/ E/S forecast medium term (2 year) growth and higher sales per share historical growth (5 years). The Russell 2000 Growth Index is constructed to provide a comprehensive and unbiased barometer for the small-cap growth segment. Please note that indexes do not take into account any fees and expenses of investing in the individual securities that they track and investors cannot invest directly in any index.

Index returns shown assume the reinvestment of all dividends and distributions.